Bristol-Myers Squibb | BMY - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Abbott USD 68M 26M 2026-03
ALKERMES USD 20.89M 8.62M 2026-03
Amgen USD 657M 4M 2026-03
AstraZeneca USD 484M 181M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 411M 21M 2026-03
Coherus Biosciences USD 2.25M 76K 2025-12
Drreddys Laboratories INR 944M 127M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
J&J USD 43M 25M 2026-03
Medtronic USD 176M 5M 2026-03
Merck USD 479M 67M 2026-03
Novartis USD 343M 39M 2026-03
Novo Nordisk DKK 1.53B 3.43B 2025-09
Perrigo USD 7.98B 7.94B 2026-03
Pfizer USD 671M 40M 2026-03
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 10.67M 636K 2025-12
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 178M 203M 2026-03
Sanofi EUR -25M 99.78M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Zoetis USD 62M 5M 2026-03